Aachen, September 2026

Dear investors, partners, and friends,

At **PL BioScience**, we are building the foundation for the future of **Cell Therapy** and **Regenerative Medicine**. Through our reliable cell culture supplements, we provide essential building blocks that help researchers and developers advance innovative therapies.

We are proud of the progress we have made in developing solutions designed to meet the evolving needs of the Regenerative Medicine community. Our work is grounded in a clear commitment to **quality**, **safety**, and **consistency**, principles that are essential for translating scientific potential into meaningful medical advances.

Our current focus is on strengthening our product portfolio, supporting our customers and partners, and expanding the capabilities needed to serve this rapidly growing field. We continue to invest in **innovation** and in the scientific and operational foundations that enable cell-based therapies to move forward with confidence.

Looking ahead, we aim to build on our strong foundation and expand our impact as a trusted global partner, providing the essential building blocks for **Cell Therapy** and **Regenerative Medicine**. By providing the essential materials for reliable cell-based science, we aim to help accelerate research, development, and, ultimately, the delivery of better solutions for patients.

We thank our investors, customers, partners, and team for their continued trust and support. Together, we are helping build the foundation for the next generation of Regenerative Medicine.

With gratitude,

Hatim Hemeda

CEO & Co-founder

Christian Wilkes

CFO & Co-founder